Fig. 4

Rapid monitoring of hospital admissions and emergency department visits following launch of the Biosimilars Initiative. Cumulative incidence of admission to hospital (A) and visit to an emergency department (B) during one year of follow-up. No periods with likelihood ratios of 7.1 or higher were detected